- Home
- SNCR vs ANVS Comparison
SNCR vs ANVS Comparison
Compare SNCR & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- ANVS
- Stock Information
- Founded
- SNCR 2000
- ANVS 2008
- Country
- SNCR United States
- ANVS United States
- Employees
- SNCR N/A
- ANVS N/A
- Industry
- SNCR EDP Services
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- SNCR Technology
- ANVS Health Care
- Exchange
- SNCR Nasdaq
- ANVS Nasdaq
- Market Cap
- SNCR 70.9M
- ANVS 48.3M
- IPO Year
- SNCR 2006
- ANVS 2020
- Fundamental
- Price
- SNCR $6.55
- ANVS $2.35
- Analyst Decision
- SNCR Strong Buy
- ANVS Strong Buy
- Analyst Count
- SNCR 1
- ANVS 4
- Target Price
- SNCR $13.00
- ANVS $17.33
- AVG Volume (30 Days)
- SNCR 62.2K
- ANVS 184.2K
- Earning Date
- SNCR 11-11-2025
- ANVS 11-07-2025
- Dividend Yield
- SNCR N/A
- ANVS N/A
- EPS Growth
- SNCR N/A
- ANVS N/A
- EPS
- SNCR N/A
- ANVS N/A
- Revenue
- SNCR $171,870,000.00
- ANVS N/A
- Revenue This Year
- SNCR $1.51
- ANVS N/A
- Revenue Next Year
- SNCR $5.43
- ANVS N/A
- P/E Ratio
- SNCR N/A
- ANVS N/A
- Revenue Growth
- SNCR 2.54
- ANVS N/A
- 52 Week Low
- SNCR $5.25
- ANVS $1.11
- 52 Week High
- SNCR $15.46
- ANVS $10.54
- Technical
- Relative Strength Index (RSI)
- SNCR 56.88
- ANVS 45.65
- Support Level
- SNCR $5.41
- ANVS $2.26
- Resistance Level
- SNCR $6.27
- ANVS $2.51
- Average True Range (ATR)
- SNCR 0.34
- ANVS 0.11
- MACD
- SNCR 0.13
- ANVS 0.01
- Stochastic Oscillator
- SNCR 94.79
- ANVS 45.16
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.